SynthesisBrain structure & function2026
Neurobiological after-effects and clinical efficacy of transcranial magnetic stimulation (TMS) in Parkinson's disease: a systematic review.
Synthesis in Brain structure & function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, deeply affecting quality of life. While pharmacological and surgical treatments like levodopa and deep brain stimulation (DBS) are standard, limitations in long-term efficacy and accessibility have led to growing interest in non-invasive neuromodulatory approaches such as transcranial magnetic stimulation (TMS). This systematic review aims to critically appraise the evidence on the clinical efficacy and neurobiological effects of TMS in PD, encompassing motor and non-motor symptom modulation, neurophysiological biomarkers, and neuroimaging findings. Following PRISMA-ScR guidelines, literature was searched in MEDLINE, EMBASE, and Scopus. Fifty eligible clinical studies were analyzed, with 28 directly addressing TMS effects on PD through clinical, neurophysiological, or imaging outcomes. High-frequency repetitive TMS (rTMS) over the primary motor cortex (M1) shows moderate efficacy in improving bradykinesia and rigidity. Stimulation of supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) yielded variable effects on gait and mood. Neurophysiological studies consistently report alterations in intracortical excitability (e.g., reduced SICI, shortened CSP), partially restored by TMS and modulated by medication or DBS. Imaging studies revealed changes in functional connectivity and dopamine release post-TMS. Notably, the clinical state ("on" vs. "off" medication), stimulation parameters, and methodological heterogeneity significantly influenced outcomes. TMS represents a promising adjunctive therapy in PD, with evidence supporting its modulatory role on cortical excitability and potential clinical benefit. However, heterogeneity in protocols, small sample sizes, and placebo effects limit definitive conclusions. Future research should prioritize standardized methodologies, exploration of optimal stimulation parameters, identification of predictive biomarkers, and integration with rehabilitative strategies to personalize treatment. Rigorous, sham-controlled trials with long-term follow-up are essential to establish TMS as a reliable therapeutic tool in PD management.
Indexed as
Identifiers
42384237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.